Thornburg Investment Management Inc. Acquires Shares of 440,624 Cellebrite DI Ltd. $CLBT

Thornburg Investment Management Inc. acquired a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 440,624 shares of the company’s stock, valued at approximately $7,944,000. Thornburg Investment Management Inc. owned about 0.18% of Cellebrite DI as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. CWM LLC lifted its position in Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the last quarter. SkyView Investment Advisors LLC lifted its position in Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after purchasing an additional 970 shares during the last quarter. Alamea Verwaltungs GmbH lifted its position in Cellebrite DI by 4.3% during the fourth quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock valued at $444,000 after purchasing an additional 1,018 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Cellebrite DI by 17.8% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,216 shares of the company’s stock valued at $220,000 after purchasing an additional 1,850 shares during the last quarter. Finally, Seelaus Asset Management LLC lifted its position in Cellebrite DI by 11.9% during the fourth quarter. Seelaus Asset Management LLC now owns 18,850 shares of the company’s stock valued at $340,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Insider Activity

In related news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the sale, the executive owned 440,101 shares in the company, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders have sold 13,269 shares of company stock valued at $169,592. 5.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CLBT. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Needham & Company LLC lowered their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Finally, DA Davidson began coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $12.84 on Monday. The firm has a 50-day moving average price of $13.23 and a 200-day moving average price of $15.03. The firm has a market capitalization of $3.20 billion, a PE ratio of 45.86, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17. Cellebrite DI Ltd. has a 12-month low of $11.02 and a 12-month high of $19.98.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.